Oppenheimer & Co’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$268K Hold
1,900
– – ﹤0.01% 1488
2026
Q2
$233K Hold
1,900
– – ﹤0.01% 1593
2026
Q1
$200K Buy
+1,900
New +$168K ﹤0.01% 1576

Other funds holding PTGX

Oppenheimer & Co's PTGX Position: Q3 2026 in Review

Oppenheimer & Co held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 1,900 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Oppenheimer & Co first reported a position in PTGX in Q1 2026 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Oppenheimer & Co held 1,900 shares of Protagonist Therapeutics worth $268K as of Q3 2026.
  • Oppenheimer & Co left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1488 holding.
  • Oppenheimer & Co first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.